Evidence based guidelines for depression screening @944@

Use of screening tools for depression in adolescents: an evidence-based systematic review By Sharolyn K. Dihigo, DNP, RN, CPNP-PC Identification and treatment of adolescent depression are national health priorities. Identifying Evidence Gaps. Specific Populations. About the USPSTF. Depression screening: adolescents: The USPSTF recommends screening for major depressive disorder (MDD) in adolescents aged 12 to 18 years. USPSTF A and B Recommendations. U.S. Preventive Services Task Force. February 2019. Screening for depression at ages 11 through 21 years has been added, along with suggested screening tools. Cholesterol screening between ages 9 and 11 years was added. A risk assessment for hematocrit or hemoglobin at ages 15 and 30 months was added. Screening for HIV was added between age 16 and 18 years. Treatment of Depression in Older Adults Evidence-Based Practices (EBP) KIT Out of Stock This kit offers information about an array of evidence-based practices for treatment and services to improve outcomes for older adults experiencing depression, including dysthymia. Screening for Depression Systematic Evidence Review Mike Pignone, MD MPH Bradley N. Gaynes, MD MPH Jerry L. Rushton, MD MPH Cynthia D. Mulrow, MD, MSc C. Tracy Orleans, PhD B. Lynn Whitener, DrPH Catherine Mills, MA Kathleen N. Lohr, PhD for the Research Triangle Institute - University of North Carolina Evidence-based Practice Center April 2002 Rationale and Evidence . Screening for adolescent depression in primary care is infrequent, 37, 38 although tools developed for primary care, but rather to provide general guidance for practitioners in the context of evidence limitations, based on guidelines, research literature, and input New Depression Screening Guidelines Released. Following a systemic review of evidence on the issue, "the USPSTF concludes with at least moderate certainty that there is a moderate net benefit Adult & Adolescent Depression Screening, Diagnosis, and recommende